CLAIMS

1. A pharmaceutical composition comprising between 30% and 50% by weight of the total composition of caprylic triglyceride, and at least one matrix forming agent present in an amount of between 20% and 70% by weight of the total composition, wherein the at least one matrix forming agent is carnauba wax or a combination of carnauba wax and glyceryl dibehenate, wherein the composition is comprised of discrete particles having an average diameter of between 50 μm and 350 μm.

2. The pharmaceutical composition of claim 1, wherein the matrix forming agent is present in an amount of between 20% and 70% by weight of the total composition.

3. The pharmaceutical composition of any of the preceding claims, wherein the matrix forming agent is present in an amount of between 40% and 70% by weight of the total composition.

4. The pharmaceutical composition of any of the preceding claims, wherein the caprylic triglyceride is present in an amount of between 40% and 50% by weight of the total composition and the matrix forming agent is present in an amount of between 50% and 60% by weight of the total composition.

5. The pharmaceutical composition of any of the preceding claims, further comprising a dissolution enhancer selected from the group consisting of poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) copolymer, polyethylene glycol copolymer, starch, rice starch, lecithin, polyvinylpyrrolidone (PVP), polyoxylglycerides, polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), hydroxypropyl methylcellulose (HPMC), hyprmellose acetate succinate (HPMCAS), Low-substituted hydroxypropyl cellulose (L-HPC), sorbitan esters, polyethylene glycol, sorbitan fatty acid esters, and combinations thereof.

6. The composition of claim 5, wherein the dissolution enhancer is present in an amount of 1% to 20% by weight of the total composition.

7. The composition of claim 5 or claim 6, wherein the dissolution enhancer is poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) copolymer.

8. A pharmaceutical composition of any of the preceding claims, further comprising a flow aid selected from the group consisting of amorphous silica gel, silica aerogel, magnesium alumino metasilicates, calcium silicate, ordered mesoporous silica, micronized talc, and combinations thereof.

9. The pharmaceutical composition of claim 8, wherein the flow aid is present in an amount of 0.1% to 5% by weight of the total composition.

10. The pharmaceutical composition of claim 8 or claim 9, wherein the flow aid is micronized talc.

11. The pharmaceutical composition of claim 1, wherein the particles have an average diameter of between 100 μm and 300 μm.

12. The pharmaceutical composition of claim 1 or claim 11, wherein the particles exhibit a Carr Index of flowability of less than 10%.

13. The pharmaceutical composition of any of the preceding claims, wherein when the pharmaceutical composition is subjected to dissolution testing using USP-II Sink dissolution post acid exposure methodology, at least 40% but not more than 60% of the caprylic triglyceride releases from the composition in the first 60 minutes, at least 60% but not more than 80% of the caprylic triglyceride releases from the composition in the 120 minutes, and at least 80% of the caprylic triglyceride releases from the composition in the first 240 minutes.

14. The pharmaceutical composition of claim 13, wherein when the pharmaceutical composition is subjected to dissolution testing using USP-II Sink dissolution post acid exposure methodology, at least 90% of the caprylic triglyceride releases from the composition in the first 360 minutes.

15. The composition of any of the preceding claims, wherein the purity of the caprylic triglyceride is at least 95%.

16. Use of a pharmaceutical composition of any of the preceding claims in the manufacture of a medicament for the treatment of a disease or disorder associated with reduced cognitive function in a subject in need thereof, wherein the pharmaceutical composition is effective to elevate ketone body concentrations in said subject to thereby treat said disease or disorder.

17. The use of claim 16, wherein the disease or disorder associated with reduced cognitive function is selected from Alzheimer's disease and Age-Associated Memory Impairment.

18. The use of claims 16 or claim 17, wherein the patient lacks the ApoE4 genotype.

19. The use of claim 17 or claim 18, wherein the medicament is to be administered at a dose of 0.05 g/kg/day to 10 g/kg/day.